Development of a novel class of interleukin-2 immunotherapies for m...
... immunotherapies for metastatic cancer. Swiss Medical Weekly, 149:w14697. Copy Abstract Tumour immunotherapy, and ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ... Development of a novel class of interleukin-2 immunotherapies for metastatic cancer - Zurich Open ...
Emerging immunotargets and immunotherapies in prostate cancer - Zur...
... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ... Emerging immunotargets and immunotherapies in prostate cancer - Zurich Open Repository and Archive ...
Immunity, Hypoxia and Metabolism - the ménage à trois of cancer: im...
... restrictive TME and as important players in the anti-tumor immune response; iii) to define how immunotherapies ... and metabolites within the TME impinge on the success of immunotherapies. By analyzing preclinical and ... restrictive TME and as important players in the anti-tumor immune response; iii) to define how immunotherapies ... and metabolites within the TME impinge on the success of immunotherapies. By analyzing preclinical and ...
http://cdr-life.com/wp-content/uploads/2018/05/PR_20180523.pdf
... of novel immunotherapies in patient biopsies ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has ... technology. The collaboration will use synergies between the modular multispecific immunotherapies from CDR ... of novel immunotherapies in patient biopsies ZURICH, Switzerland, May 23, 2018 – CDR-Life inc. has ... technology. The collaboration will use synergies between the modular multispecific immunotherapies from CDR ...
https://www.virometix.com/wp-content/uploads/2022/03/Oncometix_Job-...
... , Switzerland, towards the evaluation of nanoparticle-based cancer vaccines and immunotherapies ... vaccine targets and immunotherapies • Mammalian cell culture and experience with cancer cell lines ... , Switzerland, towards the evaluation of nanoparticle-based cancer vaccines and immunotherapies ... vaccine targets and immunotherapies • Mammalian cell culture and experience with cancer cell lines ...
Jan Kisielow, PhD • Repertoire Immune Medicines
... provide the basis for personalized immunotherapies. He earned his PhD in cell biology from the Basel ... antigenic reactivity of T cells to provide the basis for personalized immunotherapies. He earned his PhD in ...
UZH - UZH Innovation Hub - UZH spin-off Anaveon successfully closed...
... . based in the a UK. Anaveon works on a new approach for developing immunotherapies for cancer. The ... approach for developing immunotherapies for cancer. The technology was developed by Prof. Onur Boyman. The ...
UZH - Institute for Regenerative Medicine • IREM - Antibody-based R...
... immunotherapies for neurodegenerative diseases, including Aducanumab resulting from research conducted at the ... Regeneration With the advent of clinically effective immunotherapies for neurodegenerative diseases, including ...
https://www.virometix.com/wp-content/uploads/2022/01/Oncometix_Job-...
... evaluation of nanoparticle-based cancer vaccines and immunotherapies as part of a bigger team of biologists ... tests and experiments for the functional validation of novel cancer vaccine targets and immunotherapies ... evaluation of nanoparticle-based cancer vaccines and immunotherapies as part of a bigger team of biologists ... tests and experiments for the functional validation of novel cancer vaccine targets and immunotherapies ...
UZH - URPP Translational Cancer Research - Cells
... targeted inhibitors and immunotherapies. A subset of the cultures has been RNA-sequenced. The expression ... immunotherapies. A subset of the cultures has been RNA-sequenced. The expression data from these cell lines are ...
